AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16508298 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg/day for 4 weeks, 10 mg/day thereafter)
Number of subjects: 286
Study 16508298 — intervention group
Group type: COMPARATOR
Intervention: Placebo (delayed‐start group)
Number of subjects: 286
Study 14624937 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 g/kg/d protein feeding regime
Number of subjects: 50
Study 14624937 — intervention group
Group type: COMPARATOR
Intervention: Escalating isocaloric protein feeding regime (1.5, 2.0, and 2.5 g/kg/d)
Number of subjects: 50
Study 14624937 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 g/kg/d protein intake
Number of subjects: 50
Study 14624937 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral feeding
Number of subjects: 50
Study 14624937 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (if enteral feeding not tolerated)
Number of subjects: 50
Study 11965831 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol lowering therapy
Number of subjects: 0
Study 11965831 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 0
Study 11965831 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy with aspirin
Number of subjects: 0
Study 11965831 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved glycaemic control
Number of subjects: 0
Study 11965831 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinedione (pioglitazone)
Number of subjects: 0
Study 11965831 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial approach (including improved glycaemic control, aggressive management of dyslipidaemia and hypertension, anti-platelet therapy, reduction of insulin resistance)
Number of subjects: 0
Study 8911881 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol at 0.5 micrograms.min-1
Number of subjects: 7
Study 8911881 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol at 1.0 micrograms.min-1
Number of subjects: 7
Study 8911881 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol at 2.0 micrograms.min-1
Number of subjects: 7
Study 8911881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 1922250 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (2 g per day of elemental calcium in the form of calcium carbonate)
Number of subjects: 1194
Study 1922250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1194
Study 1922250 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 1194
Study 1922250 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (for women with low urinary calcium to creatinine ratio)
Number of subjects: 1194
Study 1922250 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (for women with high urinary calcium to creatinine ratio)
Number of subjects: 1194
Study 7084267 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle and arm‐assisted step test
Number of subjects: 12
Study 7084267 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill
Number of subjects: 12
Study 7084267 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm‐assisted step test
Number of subjects: 12
Study 30697793 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-supported nurse-led advance care planning program
Number of subjects: 298
Study 30697793 — intervention group
Group type: COMPARATOR
Intervention: Health education program at home
Number of subjects: 298
Study 28327089 — intervention group
Group type: EXPERIMENTAL
Intervention: De-escalation of elective radiation dose with introduction of an intermediate dose-level for selected lymph nodes.
Number of subjects: 300
Study 28327089 — intervention group
Group type: COMPARATOR
Intervention: Standard elective radiation dose without de-escalation.
Number of subjects: 300
Study 26489756 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help (GSH) based on cognitive behaviour therapy (CBT)
Number of subjects: 54
Study 26489756 — intervention group
Group type: COMPARATOR
Intervention: Standard outpatient department support (Control)
Number of subjects: 54
Study 23371748 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive loading during walking
Number of subjects: 54
Study 23371748 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive loading during standing
Number of subjects: 54
Study 23371748 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive loading during cycling
Number of subjects: 54
Study 23371748 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive loading during all tasks
Number of subjects: 54
Study 21234579 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline citrate (300.2 mg intravenously every 12 hours until defecation)
Number of subjects: 122
Study 21234579 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride, every 12 hours until defecation)
Number of subjects: 122
Study 21234579 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 122
Study 21234579 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparotomy
Number of subjects: 122
Study 21234579 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline citrate
Number of subjects: 122
Study 21234579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 19147459 — intervention group
Group type: EXPERIMENTAL
Intervention: Canrenone
Number of subjects: 382
Study 19147459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study 17306222 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet administration of the Obsessive Compulsive Inventory and the Obsessive Beliefs Questionnaire-44
Number of subjects: 0
Study 15469788 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg once a day
Number of subjects: 71
Study 15469788 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pravastatin)
Number of subjects: 71
Study 11567815 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR overexpression (positive immunoreactivity)
Number of subjects: 170
Study 11567815 — intervention group
Group type: COMPARATOR
Intervention: No EGFR immunoreactivity
Number of subjects: 170
Study 11567815 — intervention group
Group type: COMPARATOR
Intervention: Intermediate EGFR staining
Number of subjects: 170
Study 11567815 — intervention group
Group type: COMPARATOR
Intervention: Strong EGFR staining
Number of subjects: 170
Study 11567815 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 immunoreactivity or mutation status
Number of subjects: 170
Study 9586915 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiation therapy with warfarin (regimen I)
Number of subjects: 295
Study 9586915 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy and radiation therapy without warfarin (regimen II)
Number of subjects: 295
Study 9586915 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE chemotherapy
Number of subjects: 295
Study 9586915 — intervention group
Group type: EXPERIMENTAL
Intervention: PCE chemotherapy and RT
Number of subjects: 295
Study 9586915 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional state (POMS)
Number of subjects: 295
Study 8139830 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical capsaicin
Number of subjects: 24
Study 3144199 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic disodium cromoglycate (DSCG)
Number of subjects: 21
Study 3144199 — intervention group
Group type: COMPARATOR
Intervention: Hypotonic disodium cromoglycate (DSCG)
Number of subjects: 21
Study 31420057 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Nigella sativa oil (1000 mg per capsule, 2 capsules per day for 8 weeks)
Number of subjects: 0
Study 31420057 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 capsules per day for 8 weeks)
Number of subjects: 0
Study 27347857 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT) combined with eccentric training
Number of subjects: 52
Study 27347857 — intervention group
Group type: COMPARATOR
Intervention: Sham shockwave combined with eccentric training
Number of subjects: 52
Study 25733157 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-9620 (0.3mg, 1mg, 2mg, 4mg)
Number of subjects: 100
Study 25733157 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-9620
Number of subjects: 100
Study 25733157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 23541281 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance percutaneous transluminal angioplasty (PTA) of nonthrombosed AVFs
Number of subjects: 69
Study 23541281 — intervention group
Group type: COMPARATOR
Intervention: Maintenance percutaneous transluminal angioplasty (PTA) of nonthrombosed AVGs
Number of subjects: 69
Study 22026565 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech and language therapy (average 6 hours over 6 months)
Number of subjects: 730
Study 22026565 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 730
Study 19192982 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim (intervention group)
Number of subjects: 125
Study 19192982 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 125
Study 16737374 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of in-group's mass killing of the out-group
Number of subjects: 0
Study 16737374 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of collective responsibility
Number of subjects: 0
Study 16737374 — intervention group
Group type: EXPERIMENTAL
Intervention: Collective guilt
Number of subjects: 0
Study 16737374 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological strategies
Number of subjects: 0
Study 15270928 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based postnatal care (n=228)
Number of subjects: 459
Study 15270928 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based postnatal care (n=231)
Number of subjects: 459
Study 11903702 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy assessment and appropriate treatments/equipment before release
Number of subjects: 39
Study 11903702 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 39
Study 9346275 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg vaccine
Number of subjects: 0
Study 9346275 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg vaccine
Number of subjects: 0
Study 9346275 — intervention group
Group type: COMPARATOR
Intervention: Alum placebo
Number of subjects: 0
Study 7946857 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 2-ng ml-1
Number of subjects: 30
Study 7946857 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1-ng ml-1
Number of subjects: 30
Study 7946857 — intervention group
Group type: COMPARATOR
Intervention: Control (no fentanyl)
Number of subjects: 30
Study 3363295 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentagastrin
Number of subjects: 0
Study 3363295 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 0
Study 29456871 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour change intervention for midwives (face-to-face training plus information resources)
Number of subjects: 30
Study 29456871 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 30
Study 27547135 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow mononuclear cell (BMC) injections
Number of subjects: 86
Study 27547135 — intervention group
Group type: COMPARATOR
Intervention: Cell‐free injections of a placebo
Number of subjects: 86
Study 25911076 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen
Number of subjects: 0
Study 25911076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24053892 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab injections
Number of subjects: 40
Study 24053892 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab injections + laser photocoagulation
Number of subjects: 40
Study 24053892 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 40
Study 24053892 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between retinal nonperfusion area and BCVA
Number of subjects: 40
Study 21126238 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation induction with sevoflurane (S 1.5, 2.0, 2.5, 3.0)
Number of subjects: 75
Study 21126238 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) with 2.5% thiopental 5 mg/kg
Number of subjects: 75
Study 18773841 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations for interventions to prevent occupational disabilities
Number of subjects: 0
Study 16608934 — intervention group
Group type: EXPERIMENTAL
Intervention: RMET by paced tube breathing
Number of subjects: 36
Study 16608934 — intervention group
Group type: COMPARATOR
Intervention: Sham training (control)
Number of subjects: 36
Study 14552510 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training (CT), including both noncomputerized and computer‐assisted interventions, with and without strategy coaching.
Number of subjects: 0
Study 14552510 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental adaptation intervention.
Number of subjects: 0
Study 11472786 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 188
Study 11472786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study 9572337 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic perfusion only (APO)
Number of subjects: 40
Study 9572337 — intervention group
Group type: COMPARATOR
Intervention: Conventional combined aortic and portal perfusion (APP)
Number of subjects: 40
Study 8060544 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir (800 mg, four times daily)
Number of subjects: 302
Study 8060544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 3051873 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml 1% mepivacaine with epinephrine
Number of subjects: 151
Study 3051873 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml 1% mepivacaine without epinephrine
Number of subjects: 151
Study 3051873 — intervention group
Group type: COMPARATOR
Intervention: 20 ml 1% mepivacaine with and without epinephrine
Number of subjects: 151
Study 30156130 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal compress treatment
Number of subjects: 21
Study 30156130 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 21
Study 26503631 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg
Number of subjects: 79
Study 26503631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 25460341 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Cawthorne & Cooksey protocol (experimental group, n=42)
Number of subjects: 82
Study 25460341 — intervention group
Group type: COMPARATOR
Intervention: Cawthorne & Cooksey protocol (control group, n=40)
Number of subjects: 82
Study 21479583 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete resection
Number of subjects: 0
Study 21479583 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial resection
Number of subjects: 0
Study 21479583 — intervention group
Group type: EXPERIMENTAL
Intervention: BCNU wafer
Number of subjects: 0
Study 21479583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21479583 — intervention group
Group type: EXPERIMENTAL
Intervention: <90% resection with BCNU wafer
Number of subjects: 0
Study 21479583 — intervention group
Group type: COMPARATOR
Intervention: <90% resection with placebo
Number of subjects: 0
Study 21479583 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 0
Study 21479583 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 0
Study 18762532 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet legislation introduced in October 1995 for bicyclists <18 years of age
Number of subjects: 362
Study 16204325 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg b.d.)
Number of subjects: 0
Study 16204325 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (20 mg mane)
Number of subjects: 0
Study 12669760 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual masking by object substitution
Number of subjects: 0
Study 12669760 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative hypothesis regarding early-stage visual processes
Number of subjects: 0
Study 11112113 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 250 microg twice daily, FP 500 microg twice daily, FP 1,000 microg twice daily
Number of subjects: 66
Study 11112113 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (BUD) 400 microg twice daily, BUD 800 microg twice daily, BUD 1,600 microg twice daily
Number of subjects: 66
Study 11112113 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 66
Study 9190973 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hormone replacement therapy (HRT)
Number of subjects: 105
Study 9190973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 1539817 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25% mepivacaine with bicarbonate
Number of subjects: 0
Study 1539817 — intervention group
Group type: COMPARATOR
Intervention: 1.25% mepivacaine without bicarbonate (placebo)
Number of subjects: 0
Study 30282450 — intervention group
Group type: EXPERIMENTAL
Intervention: 8th edition AJCC staging system
Number of subjects: 1633
Study 30282450 — intervention group
Group type: COMPARATOR
Intervention: 7th edition AJCC staging system
Number of subjects: 1633
Study 29685740 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital group (Verion®, Alcon)
Number of subjects: 30
Study 29685740 — intervention group
Group type: COMPARATOR
Intervention: Ink-marking group (Pendular marker, AMO)
Number of subjects: 30
Study 26108524 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear-acupoint pressing combined with Ear Apex (HX6,7) bloodletting
Number of subjects: 180
Study 26108524 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins C and E with 0.025% tretinoin cream
Number of subjects: 180
Study 26108524 — intervention group
Group type: COMPARATOR
Intervention: Urea-cream (placebo)
Number of subjects: 180
Study 25014687 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide (120 mg, once every 28 days for 96 weeks)
Number of subjects: 204
Study 25014687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 25014687 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide
Number of subjects: 204
Study 23060037 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg daily)
Number of subjects: 1824
Study 23060037 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (200 μg daily as selenized yeast)
Number of subjects: 1824
Study 23060037 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 1824
Study 23060037 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 1824
Study 21252608 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative autotransfusion in knee arthroplasty
Number of subjects: 74
Study 21252608 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative autotransfusion in hip arthroplasty
Number of subjects: 74
Study 21252608 — intervention group
Group type: COMPARATOR
Intervention: Control group in knee arthroplasty
Number of subjects: 74
Study 21252608 — intervention group
Group type: COMPARATOR
Intervention: Control group in hip arthroplasty
Number of subjects: 74
Study 18040528 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml elderberry extract (278 mg total anthocyanins)
Number of subjects: 6
Study 18040528 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ml elderberry extract (1852 mg total anthocyanins)
Number of subjects: 6
Study 16199360 — intervention group
Group type: EXPERIMENTAL
Intervention: Large class Integrated Learning Activity (ILA)
Number of subjects: 246
Study 16199360 — intervention group
Group type: COMPARATOR
Intervention: Traditional small group facilitated PBL sessions
Number of subjects: 246
Study 12380791 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg orally once daily for 3 weeks
Number of subjects: 31
Study 12380791 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (cefazolin plus gentamicin/cephalexin) for 3 to 4 weeks
Number of subjects: 31
Study 10428221 — intervention group
Group type: EXPERIMENTAL
Intervention: Charnley total hip arthroplasty
Number of subjects: 410
Study 10428221 — intervention group
Group type: COMPARATOR
Intervention: Spectron total hip arthroplasty
Number of subjects: 410
Study 7593727 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 712
Study 2290723 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC I (0.5% tetracaine, 1:2000 Adrenalin, 11.8% cocaine)
Number of subjects: 250
Study 2290723 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC II (1.0% tetracaine, 1:4000 Adrenalin, 7.0% cocaine)
Number of subjects: 250
Study 2290723 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC III (1.0% tetracaine, 1:4000 Adrenalin, 4.0% cocaine)
Number of subjects: 250
Study 2290723 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC (all formulations)
Number of subjects: 250
Study 6937648 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diazepam
Number of subjects: 10
Study 6937648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30099692 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk information presented as icon arrays
Number of subjects: 19
Study 30099692 — intervention group
Group type: COMPARATOR
Intervention: Risk information presented as percentages
Number of subjects: 19
Study 28710178 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovaza (1.86 g of EPA and 1.5 g of DHA daily)
Number of subjects: 262
Study 28710178 — intervention group
Group type: COMPARATOR
Intervention: Control (no Lovaza)
Number of subjects: 262
Study 26051571 — intervention group
Group type: EXPERIMENTAL
Intervention: Ren Shen Yang Rong Tang (R-S-Y-R-T)
Number of subjects: 59
Study 26051571 — intervention group
Group type: COMPARATOR
Intervention: Routine western medicine
Number of subjects: 59
Study 23977977 — intervention group
Group type: EXPERIMENTAL
Intervention: Framing therapeutic benefits as improvements in landmark survival
Number of subjects: 2040